Lipella Pharmaceuticals Inc. (LIPO) Dividend History

Company News

• Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

  Lipella Pharmaceuticals has completed enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The company expects to report topline results from the final cohort in the second quarter of 2025.

  GlobeNewswire Inc.
• Spartan Capital Securities, LLC Announces Key February Transactions

  Spartan Capital Securities, a full-service investment banking firm, has successfully completed a series of strategic transactions, including serving as the sole placement agent for Lipella Pharmaceuticals and co-placement agent for Healthcare Triangle's private placements. These transactions highlight Spartan Capital's ability to deliver meaningful results for its clients and support their growth initiatives.

  GlobeNewswire Inc.

  Featured Companies: HCTI
• Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

  Lipella Pharmaceuticals reported positive results from a Phase 2a trial of its LP-310 oral rinse for treating oral lichen planus, a chronic inflammatory condition. The trial showed significant improvements in pain, ulceration, and inflammation, with a favorable safety profile.

  GlobeNewswire Inc.
• Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

  Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for its oral rinse formulation LP-310 to treat oral lichen planus, a chronic inflammatory condition with no FDA-approved therapies.

  GlobeNewswire Inc.
• Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

  Spartan Capital Securities, LLC acted as the sole placement agent in two private offerings of Series B non-voting convertible preferred stock for Lipella Pharmaceuticals Inc., raising a total of $875,500. The proceeds will support Lipella's clinical pipeline and corporate purposes.

  GlobeNewswire Inc.